Darbepoetin alfa (INN) /dɑːrbəˈpoʊɪtɪn/ is a re-engineered form of erythropoietin containing 5 amino acid changes (N30, T32, V87, N88, T90) resulting in the creation of 2 new sites for N-linked carbohydrate addition. It has a 3-fold longer serum half-life compared to epoetin alpha and epoetin beta. It stimulates erythropoiesis (increases red blood cell levels) by the same mechanism as rHuEpo (binding and activating the Epo receptor) and is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy. Darbepoetin is marketed by Amgen under the trade name Aranesp.
The medication was approved in September 2001, by the US Food and Drug Administration for treatment of anemia in patients with chronic kidney failure by intravenous or subcutaneous injection.[3] In June 2001, it had been approved by the European Medicines Agency for this indication as well as the treatment of anemia in cancer patients undergoing chemotherapy.[4]
Dr. Reddy's Laboratories launched darbepoetin alfa in India under the brand name ‘Cresp’ in August 2010. This is the world's first follow-on biologic of darbepoetin alfa.
Darbepoetin is produced by recombinant DNA technology in modified Chinese hamster ovary cells.[5] It differs from endogenous erythropoietin (EPO) by containing two more N-linked oligosaccharide chains. It is an erythropoiesis-stimulating 165-amino acid protein.
It is on the World Health Organization's List of Essential Medicines.[6]
^"Darbepoetin alfa (Aranesp) Use During Pregnancy". Drugs.com. 31 December 2018. Retrieved 7 April 2020.
^"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
^Siegel JP (17 September 2001). "Product Approval Information - Licensing Action". United States Food and Drug Administration. Archived from the original on 22 October 2006. Retrieved 27 January 2007.
^"European Public Assessment Report (Abstract)" (PDF). European Medicines Agency. 8 June 2001. Archived from the original (PDF) on 17 October 2006. Retrieved 27 January 2007.
^Smith RE, Jaiyesimi IA, Meza LA, Tchekmedyian NS, Chan D, Griffith H, et al. (April 2001). "Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer". British Journal of Cancer. 84 Suppl 1 (s1): 24–30. doi:10.1054/bjoc.2001.1749. PMC 2363901. PMID 11308271.
^World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
agreement. The average cost per patient in the U.S. was $8,447 in 2009.Darbepoetinalfa (rINN) /dɑːrbəˈpɔɪtɪn/ is a glycosylation analog of erythropoietin...
technology in cell culture, and include Epogen/Procrit (epoetin alfa) and Aranesp (darbepoetinalfa); they are used in treating anemia resulting from chronic...
Interferon alfa (INN) or HuIFN-alpha-Le, trade name Multiferon, is a pharmaceutical drug composed of natural interferon alpha (IFN-α), obtained from the...
remain in the body longer. This led to the development of Aranesp (darbepoetinalfa). 1998: In November 1998, Immunex, a future acquisition of Amgen, received...
interferon alfa. The recombinant type is interferon alfacon-1. The pegylated types are pegylated interferon alfa-2a and pegylated interferon alfa-2b. Recombinant...
as:[citation needed] Epoetin alfa, a synthetic erythropoietin that stimulates stem cells to produce red blood cells. Darbepoetinalfa stimulates red blood cells...
anemia in the United States are epoetin alfa (sold under the names Procrit and Epogen) and darbepoetinalfa (which is a more glycosylated form of epoetin...
defined as the use of illicit products (e.g. erythropoietin (EPO), darbepoetin-alfa, hypoxia-inducible factor (HIF) stabilizers) and methods (e.g. increase...
3 to 4 weeks demonstrated efficacy similar to that of epoetin alfa and darbepoetinalfa in maintaining hemoglobin concentrations within the target hemoglobin...
Shepherd J, Waugh N, Hewitson P (2000). "Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic...